This NVIDIA Partnership Shows How Big AI Can Really Get

Core Insights - NVIDIA's market is experiencing significant growth, with a long-term outlook suggesting a valuation that is currently undervalued, trading at 40x earnings in early 2026, and potentially offering 200% to 500% gains over the next decade [3][4] Company Developments - NVIDIA has entered a $1 billion partnership with Eli Lilly to develop an AI supercomputer aimed at accelerating drug discovery and manufacturing processes, marking a significant expansion beyond its traditional GPU market [4][5] - The collaboration will utilize a loop-style system where AI-generated discoveries assist physicians, and in turn, physicians will enhance AI models, thereby transforming the drug discovery industry [5] Market Potential - The drug discovery market is valued at over $105 billion as of the end of 2025, with a projected high-single-digit growth rate of nearly 10% annually [6] - AI-enabled drug discovery currently represents less than 20% of the market but is expected to grow sixfold in the next eight years, indicating substantial future opportunities [6] - The drug discovery sector serves as a gateway to the more lucrative drug production and sales market, which exceeds $550 million in the US alone [6]